Investors Cheer Armata Pharma’s Encouraging Data From Lung Infection Candidate
Armata Pharmaceuticals Inc (NASDAQ:ARMP) announced positive topline results from the completed Phase 1b/2a SWARM-P.a. trial evaluating AP-PA02 for chronic pulmonary Pseudomonas aeruginosa infections in…